Literature DB >> 24285858

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.

Richard M Brohet1, Maria E Velthuizen, Frans B L Hogervorst, Hanne E J Meijers-Heijboer, Caroline Seynaeve, Margriet J Collée, Senno Verhoef, Margreet G E M Ausems, Nicoline Hoogerbrugge, Christi J van Asperen, Encarna Gómez García, Fred Menko, Jan C Oosterwijk, Peter Devilee, Laura J van't Veer, Flora E van Leeuwen, Douglas F Easton, Matti A Rookus, Antonis C Antoniou.   

Abstract

BACKGROUND: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks have been found to vary across studies and populations.
METHODS: We ascertained pedigree data of 582 BRCA1 and 176 BRCA2 families and studied the variation in breast and ovarian cancer risks using a modified segregation analysis model.
RESULTS: The average cumulative breast cancer risk by age 70 years was estimated to be 45% (95% CI 36 to 52%) for BRCA1 and 27% (95% CI 14 to 38%) for BRCA2 mutation carriers. The corresponding cumulative risks for ovarian cancer were 31% (95% CI 17 to 43%) for BRCA1 and 6% (95% CI 2 to 11%) for BRCA2 mutation carriers. In BRCA1 families, breast cancer relative risk (RR) increased with more recent birth cohort (p heterogeneity = 0.0006) and stronger family histories of breast cancer (p heterogeneity < 0.001). For BRCA1, our data suggest a significant association between the location of the mutation and the ratio of breast to ovarian cancer (p<0.001). By contrast, in BRCA2 families, no evidence was found for risk heterogeneity by birth cohort, family history or mutation location.
CONCLUSIONS: BRCA1 mutation carriers conferred lower overall breast and ovarian cancer risks than reported so far, while the estimates of BRCA2 mutations were among the lowest. The low estimates for BRCA1 might be due to older birth cohorts, a moderate family history, or founder mutations located within specific regions of the gene. These results are important for a more accurate counselling of BRCA1/2 mutation carriers.

Entities:  

Keywords:  Cancer: Breast; Clinical Genetics; Genetic Epidemiology; Oncology

Mesh:

Year:  2013        PMID: 24285858     DOI: 10.1136/jmedgenet-2013-101974

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  27 in total

Review 1.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

2.  The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?

Authors:  Natalia Teixeira; Annemieke van der Hout; Jan C Oosterwijk; Janet R Vos; Peter Devilee; Klaartje van Engelen; Hanne Meijers-Heijboer; Rob B van der Luijt; Mieke Kriege; Arjen R Mensenkamp; Matti A Rookus; Kees E van Roozendaal; Marian J E Mourits; Geertruida H de Bock
Journal:  Eur J Hum Genet       Date:  2018-02-26       Impact factor: 4.246

3.  The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.

Authors:  Maiko Okano; Tadashi Nomizu; Kazunoshin Tachibana; Miki Nagatsuka; Masami Matsuzaki; Naoto Katagata; Toru Ohtake; Shiro Yokoyama; Masami Arai; Seigo Nakamura
Journal:  J Hum Genet       Date:  2020-10-12       Impact factor: 3.172

4.  Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.

Authors:  P Riedlova; J Janoutova; B Hermanova
Journal:  Mol Biol Rep       Date:  2020-03-16       Impact factor: 2.316

5.  Return of Results from Genomic Sequencing: A Policy Discussion of Secondary Findings for Cancer Predisposition.

Authors:  Kimberly J Johnson; Sarah Gehlert
Journal:  J Cancer Policy       Date:  2014-09-01

6.  BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Authors:  Huong D Meeks; Honglin Song; Kyriaki Michailidou; Manjeet K Bolla; Joe Dennis; Qin Wang; Daniel Barrowdale; Debra Frost; Lesley McGuffog; Steve Ellis; Bingjian Feng; Saundra S Buys; John L Hopper; Melissa C Southey; Andrea Tesoriero; Paul A James; Fiona Bruinsma; Ian G Campbell; Annegien Broeks; Marjanka K Schmidt; Frans B L Hogervorst; Matthias W Beckman; Peter A Fasching; Olivia Fletcher; Nichola Johnson; Elinor J Sawyer; Elio Riboli; Susana Banerjee; Usha Menon; Ian Tomlinson; Barbara Burwinkel; Ute Hamann; Frederik Marme; Anja Rudolph; Ramunas Janavicius; Laima Tihomirova; Nadine Tung; Judy Garber; Daniel Cramer; Kathryn L Terry; Elizabeth M Poole; Shelley S Tworoger; Cecilia M Dorfling; Elizabeth J van Rensburg; Andrew K Godwin; Pascal Guénel; Thérèse Truong; Dominique Stoppa-Lyonnet; Francesca Damiola; Sylvie Mazoyer; Olga M Sinilnikova; Claudine Isaacs; Christine Maugard; Stig E Bojesen; Henrik Flyger; Anne-Marie Gerdes; Thomas V O Hansen; Allen Jensen; Susanne K Kjaer; Claus Hogdall; Estrid Hogdall; Inge Sokilde Pedersen; Mads Thomassen; Javier Benitez; Anna González-Neira; Ana Osorio; Miguel de la Hoya; Pedro Perez Segura; Orland Diez; Conxi Lazaro; Joan Brunet; Hoda Anton-Culver; Lee Eunjung; Esther M John; Susan L Neuhausen; Yuan Chun Ding; Danielle Castillo; Jeffrey N Weitzel; Patricia A Ganz; Robert L Nussbaum; Salina B Chan; Beth Y Karlan; Jenny Lester; Anna Wu; Simon Gayther; Susan J Ramus; Weiva Sieh; Alice S Whittermore; Alvaro N A Monteiro; Catherine M Phelan; Mary Beth Terry; Marion Piedmonte; Kenneth Offit; Mark Robson; Douglas Levine; Kirsten B Moysich; Rikki Cannioto; Sara H Olson; Mary B Daly; Katherine L Nathanson; Susan M Domchek; Karen H Lu; Dong Liang; Michelle A T Hildebrant; Roberta Ness; Francesmary Modugno; Leigh Pearce; Marc T Goodman; Pamela J Thompson; Hermann Brenner; Katja Butterbach; Alfons Meindl; Eric Hahnen; Barbara Wappenschmidt; Hiltrud Brauch; Thomas Brüning; Carl Blomqvist; Sofia Khan; Heli Nevanlinna; Liisa M Pelttari; Kristiina Aittomäki; Ralf Butzow; Natalia V Bogdanova; Thilo Dörk; Annika Lindblom; Sara Margolin; Johanna Rantala; Veli-Matti Kosma; Arto Mannermaa; Diether Lambrechts; Patrick Neven; Kathleen B M Claes; Tom Van Maerken; Jenny Chang-Claude; Dieter Flesch-Janys; Florian Heitz; Raymonda Varon-Mateeva; Paolo Peterlongo; Paolo Radice; Alessandra Viel; Monica Barile; Bernard Peissel; Siranoush Manoukian; Marco Montagna; Cristina Oliani; Ana Peixoto; Manuel R Teixeira; Anita Collavoli; Emily Hallberg; Janet E Olson; Ellen L Goode; Steven N Hart; Hermela Shimelis; Julie M Cunningham; Graham G Giles; Roger L Milne; Sue Healey; Kathy Tucker; Christopher A Haiman; Brian E Henderson; Mark S Goldberg; Marc Tischkowitz; Jacques Simard; Penny Soucy; Diana M Eccles; Nhu Le; Anne-Lise Borresen-Dale; Vessela Kristensen; Helga B Salvesen; Line Bjorge; Elisa V Bandera; Harvey Risch; Wei Zheng; Alicia Beeghly-Fadiel; Hui Cai; Katri Pylkäs; Robert A E M Tollenaar; Ans M W van der Ouweland; Irene L Andrulis; Julia A Knight; Steven Narod; Peter Devilee; Robert Winqvist; Jonine Figueroa; Mark H Greene; Phuong L Mai; Jennifer T Loud; Montserrat García-Closas; Minouk J Schoemaker; Kamila Czene; Hatef Darabi; Iain McNeish; Nadeem Siddiquil; Rosalind Glasspool; Ava Kwong; Sue K Park; Soo Hwang Teo; Sook-Yee Yoon; Keitaro Matsuo; Satoyo Hosono; Yin Ling Woo; Yu-Tang Gao; Lenka Foretova; Christian F Singer; Christine Rappaport-Feurhauser; Eitan Friedman; Yael Laitman; Gad Rennert; Evgeny N Imyanitov; Peter J Hulick; Olufunmilayo I Olopade; Leigha Senter; Edith Olah; Jennifer A Doherty; Joellen Schildkraut; Linetta B Koppert; Lambertus A Kiemeney; Leon F A G Massuger; Linda S Cook; Tanja Pejovic; Jingmei Li; Ake Borg; Anna Öfverholm; Mary Anne Rossing; Nicolas Wentzensen; Karin Henriksson; Angela Cox; Simon S Cross; Barbara J Pasini; Mitul Shah; Maria Kabisch; Diana Torres; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Bjarni A Agnarsson; Jolanta Kupryjanczyk; Joanna Moes-Sosnowska; Florentia Fostira; Irene Konstantopoulou; Susan Slager; Michael Jones; Antonis C Antoniou; Andrew Berchuck; Anthony Swerdlow; Georgia Chenevix-Trench; Alison M Dunning; Paul D P Pharoah; Per Hall; Douglas F Easton; Fergus J Couch; Amanda B Spurdle; David E Goldgar
Journal:  J Natl Cancer Inst       Date:  2015-11-19       Impact factor: 13.506

7.  Association of infertility with premature mortality among US women: Prospective cohort study.

Authors:  Yi-Xin Wang; Leslie V Farland; Siwen Wang; Audrey J Gaskins; Liang Wang; Janet W Rich-Edwards; Rulla Tamimi; Stacey A Missmer; Jorge E Chavarro
Journal:  Lancet Reg Health Am       Date:  2021-11-16

8.  Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.

Authors:  Alexandra J van den Broek; Karen de Ruiter; Laura J van 't Veer; Rob A E M Tollenaar; Flora E van Leeuwen; Senno Verhoef; Marjanka K Schmidt
Journal:  Eur J Hum Genet       Date:  2014-08-20       Impact factor: 4.246

9.  Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.

Authors:  M R Wevers; M K Schmidt; E G Engelhardt; S Verhoef; M J Hooning; M Kriege; C Seynaeve; M Collée; C J van Asperen; R A E M Tollenaar; L B Koppert; A J Witkamp; E J T Rutgers; N K Aaronson; M A Rookus; M G E M Ausems
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

Review 10.  Infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases.

Authors:  Juan J Tarín; Miguel A García-Pérez; Toshio Hamatani; Antonio Cano
Journal:  Reprod Biol Endocrinol       Date:  2015-04-15       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.